Linagliptina Sandoz (Linagliptin)

Linagliptin is used to treat disorders of glucose metabolism, primarily type 2 diabetes mellitus.

• Type 2 diabetes mellitus (monotherapy): improves glycemic control as a single oral agent.
• Type 2 diabetes mellitus (combined with metformin): enhances glucose‑lowering effect when added to metformin therapy.
• Type 2 diabetes mellitus (combined with insulin): provides additional glycemic reduction alongside insulin regimens.

• Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which degrades the incretin hormones glucagon‑like peptide‑1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP). By blocking DPP‑4, linagliptin raises endogenous GLP‑1 and GIP levels, leading to glucose‑dependent stimulation of insulin secretion and suppression of glucagon release, thereby lowering post‑prandial and fasting blood glucose concentrations.

Linagliptin may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nasopharyngitis: mild inflammation of the nose and throat.
• Headache: transient cranial pain.
• Upper respiratory tract infection: symptoms of cough and congestion.
• Dizziness: occasional sense of light‑headedness.

Serious or Rare Side Effects

• Pancreatitis: severe abdominal pain requiring immediate medical attention.
• Severe allergic reactions: including rash, angioedema, or anaphylaxis.
• Hepatic injury: elevated liver enzymes or jaundice.

When prescribing linagliptin, clinicians should consider several precautionary measures to ensure patient safety.

• Renal impairment: assess kidney function and monitor for any changes.
• Hepatic impairment: evaluate liver enzymes before initiation and periodically thereafter.
• Cardiovascular disease: use with caution in patients with established heart disease.
• Pregnancy and lactation: safety data are limited; prescribe only if potential benefit justifies the risk.
• Concomitant use with sulfonylureas or insulin: increased risk of hypoglycemia; monitor glucose levels closely.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Linagliptin can interact with other medicines, and the significance of these interactions varies.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure and risk of adverse effects.
• Co‑administration with insulin or sulfonylureas: heightened risk of hypoglycemia; avoid unless dose adjustments are made.

Moderate Interactions (Monitor Closely)

• Metformin: monitor renal function as combined therapy may affect renal clearance.
• Rifampin: may reduce linagliptin plasma concentrations, decreasing efficacy.
• Diuretics: observe for fluid‑electrolyte changes when used together.
• ACE inhibitors: no clinically significant interaction, but routine monitoring is advisable.